Development
Novartis AG
NVS
$117.76
$0.91990.79%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 381.54% | -23.96% | 1.00% | 56.41% | -6.80% |
| Total Depreciation and Amortization | -12.92% | 11.43% | -20.84% | 16.93% | 0.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -880.00% | 1,925.00% | -102.90% | 11.65% | -24.17% |
| Change in Net Operating Assets | -179.85% | 675.63% | 105.39% | -1,760.15% | -47.64% |
| Cash from Operations | -32.45% | 32.27% | 20.93% | -28.07% | -12.92% |
| Capital Expenditure | -55.56% | -67.31% | 34.18% | 22.55% | -38.46% |
| Sale of Property, Plant, and Equipment | 221.57% | 610.00% | -131.25% | -68.63% | 410.00% |
| Cash Acquisitions | 99.83% | -4,001.19% | -223.08% | -1,200.00% | -- |
| Divestitures | -200.00% | -87.50% | 223.08% | -160.00% | -162.50% |
| Other Investing Activities | -204.79% | 275.95% | -107.54% | 965.05% | -123.30% |
| Cash from Investing | 20.43% | -110.07% | -109.91% | 823.99% | -128.22% |
| Total Debt Issued | -- | -- | -- | 185.62% | -- |
| Total Debt Repaid | 102.37% | -1,255.56% | 412.00% | -17.19% | 96.90% |
| Issuance of Common Stock | -- | -- | -100.63% | -- | -- |
| Repurchase of Common Stock | 22.71% | 45.05% | -2.46% | -7.77% | 1.47% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 100.00% | -- | -- |
| Other Financing Activities | -98.88% | 3,050.45% | 165.68% | -201.79% | -230.23% |
| Cash from Financing | 27.04% | 77.12% | 60.48% | -130.40% | 15.70% |
| Foreign Exchange rate Adjustments | 196.39% | -16,500.00% | -100.93% | -24.11% | 276.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.00% | 236.32% | -124.87% | 470.80% | -123.70% |